Gen-Probe

Former QuidelOrtho CEO Douglas Bryant Joins Board of Directors of Vital Biosciences

Retrieved on: 
Tuesday, April 9, 2024
Software, Research, General Health, Hardware, Data Management, Technology, Medical Devices, Health Technology, Clinical Trials, Science, FDA, Health, Other Science, San Diego Business Journal, Abbott Laboratories, EVP, QuidelOrtho, COVID-19, Patient, Luminex Corporation, Banda della Magliana, Acquisition, Labcorp, Vasu, Gen-Probe, Ortho Clinical Diagnostics, Blood, Management

Vital Biosciences today announced that Mr. Douglas Bryant has joined the company’s Board of Directors.

Key Points: 
  • Vital Biosciences today announced that Mr. Douglas Bryant has joined the company’s Board of Directors.
  • Vital Biosciences announced its work on a revolutionary new product, the VitalOne.
  • “Doug grew QuidelOrtho into a global leader in diagnostics, and a category defining company in point-of-care,” according to Vasu Nadella, CEO of Vital Biosciences.
  • He led the company during the acquisition of Ortho Clinical Diagnostics and subsequent renaming to QuidelOrtho in May 2022.

Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Sigma-Aldrich, Epigenomics, Cornell University, MAI, Bruker, Abraxis BioScience, Principal, Biotechnology, Research, General partnership, Viridos (company), NGS, St. Louis, Biophysics, Protein engineering, Doctor of Philosophy, Gen-Probe, Synthetic biology, Gene editing, Cell biology, Dicarboxylic acid, Gene, Oligonucleotide, Thermo Fisher Scientific, Genomics, Horizon Discovery, CTAB, DNA, Fine chemical

"With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.

Key Points: 
  • "With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "Molecular Assemblies is helping accelerate the life science industry by removing one of the largest bottlenecks in R&D – the availability of long, pure, accurate oligonucleotides," said Todd C. Peterson, Ph.D., CTAB Chair and MAI Board Director.
  • He is currently Founder and Principal at GenApex Bio, a life sciences Board service and advisory practice.
  • His extensive experience includes leadership roles at Sigma-Aldrich and Genome Systems, where he made significant contributions to the genomics field.

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious Diseases, Health Technology, Gen-Probe, Polymerase, NGS, Coagulation, Hepatitis, Fungal infection, Medicine, Infection, NAT, Molecular diagnostics, Geography, Urine, Roche, IVD, TB, Respiratory disease, Developed country, Gene, Human leukocyte antigen, Cancer, Prognosis, Single-nucleotide polymorphism, Risk, Polymerase chain reaction, HLA, Safety, COVID-19, Massive parallel sequencing, Immunoassay, Physician, HIV, BD (company), HPV, DSM-IV codes, PCR, AMR, Metabolism, Pharmacokinetics, Diagnosis, Blood, Growth, Vaccine

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

Molecular HPV Testing: 6.6% Revenue Growth 2023-2028, reports Kalorama Information

Retrieved on: 
Thursday, January 11, 2024
Gen-Probe, World Health Organization, Medicine, Incidence, Molecular diagnostics, Roche, TB, Tuberculosis, Cancer, Workflow, Vaccination, Risk, Infection, Sale, PAP, Cervical cancer, Food, WHO, COVID-19, STI, FDA, HIV, BD (company), HERE, HPV, Treatment, News, Growth, Vaccine

ARLINGTON, Va., Jan. 11, 2024 /PRNewswire-PRWeb/ -- Human papillomavirus (HPV) testing is a key segment of the double-digit, multi-billion-dollar global molecular diagnostic testing market, according to The World Market for Molecular Diagnostics, 12th Edition, a new report published by leading medical market research firm Kalorama Information. The report reveals that through 2028, molecular HPV testing will grow 6.6%—outpacing growth in several other notable molecular testing segments including HIV, STIs, and genetic/inherited diseases.

Key Points: 
  • ARLINGTON, Va., Jan. 11, 2024 /PRNewswire-PRWeb/ -- Human papillomavirus (HPV) testing is a key segment of the double-digit, multi-billion-dollar global molecular diagnostic testing market, according to The World Market for Molecular Diagnostics, 12th Edition , a new report published by leading medical market research firm Kalorama Information.
  • The report reveals that through 2028, molecular HPV testing will grow 6.6%—outpacing growth in several other notable molecular testing segments including HIV, STIs, and genetic/inherited diseases.
  • Today, molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare, according to Kalorama Information.
  • Recently growth in molecular diagnostics methods has also been coming from cancer, TB, ISH/ FISH, and other areas.

Serimmune Announces Appointment of Dr. Gary Schroth to its Scientific Advisory Board

Retrieved on: 
Monday, August 7, 2023
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, SAB, Bachelor, Bachelor of Science, University, Applied Biosystems, Biochemistry, Davis, NGS, Infection, Cancer, United States Air Force Scientific Advisory Board, Disease, Thermo Fisher Scientific, Genomics, Doctor of Philosophy, Gen-Probe, Microbiology, Management, Illumina

Serimmune, a leader in understanding the antibody repertoire’s role in human disease, announced today the appointment of Gary Schroth, PhD, Vice President and Distinguished Scientist at Illumina, to its Scientific Advisory Board (SAB).

Key Points: 
  • Serimmune, a leader in understanding the antibody repertoire’s role in human disease, announced today the appointment of Gary Schroth, PhD, Vice President and Distinguished Scientist at Illumina, to its Scientific Advisory Board (SAB).
  • As an industry veteran in genomics and next-generation sequencing (NGS), Dr. Schroth brings more than 25 years of scientific and leadership experience to this role.
  • Dr. Schroth uses NGS tools in his research to study gene structure, expression and regulation as it applies to cancer, functional genomics, immunology, microbiology and infectious disease.
  • He earned both his PhD and Bachelor of Science in biochemistry from the University of California at Davis.

2023 Healthcare Trend: Growth in $21 Billion Molecular Diagnostics Market

Retrieved on: 
Tuesday, January 3, 2023
Knowledge, Infection, Roche Diagnostics, RT, COVID, Knowledge-centered support, Gen-Probe, BD (company), Growth, COVID-19, Tuberculosis, Publishing, Neisseria gonorrhoeae, HIV, Coagulation, IVD, Cancer, Chlamydia trachomatis, Pharmaceutical industry, Science

ARLINGTON, Va., Jan. 3, 2023 /PRNewswire-PRWeb/ -- There is a market in excess of $21 billion for molecular testing technologies, reveals medical market research publisher Kalorama Information in The World Market for Molecular Diagnostics Tests, 11th Edition, a recent report added to the firm's Knowledge Center subscription. The majority of the market is COVID-19, but there remains a $10 billion dollar market for all other molecular in vitro diagnostics (IVD).

Key Points: 
  • ARLINGTON, Va., Jan. 3, 2023 /PRNewswire-PRWeb/ -- There is a market in excess of $21 billion for molecular testing technologies, reveals medical market research publisher Kalorama Information in The World Market for Molecular Diagnostics Tests, 11th Edition , a recent report added to the firm's Knowledge Center subscription .
  • The majority of the market is COVID-19, but there remains a $10 billion dollar market for all other molecular in vitro diagnostics (IVD).
  • Kalorama Information estimates a $11 billion dollar market for 2022 for COVID-19 molecular diagnostics testing.
  • "Recent growth in molecular diagnostics methods has also been coming from inherited diseases, cancer, coagulation, and other areas."

United States Molecular Diagnostics Market Analysis Report 2022: A $12.5 Billion Market by 2027 - Industry Trends, Growth, Insights, Impact of COVID-19, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
Health, Biotechnology, COVID-19, Diagnosis, BioMérieux, Laboratory, Infection, Cell, Gene, United States national laboratories, Abbott Laboratories, Myriad Genetics, Roche Diagnostics, Projection, Patient, POC, Proteome, Government, Gen-Probe, NHS England, Ageing, Cancer, Genome, Protein, FISH, RNA transfection, PCR, Abbott, Power-on self-test, ID, Prognosis, Genetic testing, Death, CE, ISH, Research, Real-time polymerase chain reaction, Danaher Corporation, Cobas, Coronavirus, NHS, England, Investment, Pharmaceutical industry, Medical device, Medical imaging, Growth

The "United States Molecular Diagnostics Market, Size, Share, Forecast 2022-2027, Industry Trends, Growth, Insights, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Molecular Diagnostics Market, Size, Share, Forecast 2022-2027, Industry Trends, Growth, Insights, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Molecular diagnostics has developed as a superior methodology in the United States over the previous decade, achieving the goal of speedier disease diagnosis with fewer complexities.
  • The COVID-19 outbreak is expected to boost the growth of the Molecular Diagnostics Market in the United States.
  • In the United States molecular diagnostics market in 2021, the infectious illness category held the most significant market share.

Global Tissue Diagnostics Market Report 2022: Developing Infrastructure for Cancer Diagnosis Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, September 26, 2022
Health, Biotechnology, Laboratory, Histology, Hospital, Prevalence, NSCLC, Breast cancer, Growth, IHC, ISH, Row, USD, Antibody, Automation, Research, Awareness, Conditional sentence, CAGR, Medical imaging, Oil, Lymphoma, Gen-Probe, Asia-Pacific, Technology, Disease

The "Tissue Diagnostics Market by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology (ISH, IHC, Special Staining), Disease (Breast Cancer, NSCLC, Lymphoma), End User (Hospitals, Research Laboratories) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tissue Diagnostics Market by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology (ISH, IHC, Special Staining), Disease (Breast Cancer, NSCLC, Lymphoma), End User (Hospitals, Research Laboratories) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global Tissue Diagnostics market is growing at a CAGR of 6.6% during and it is expected to reach USD 7.3 billion by 2027 from USD 5.3 billion in 2022, during the forecast period.
  • Based on the product, the tissue diagnostics market is classified into tissue diagnostics consumables (Antibodies, Kits, Reagents, Probes) and tissue diagnostics Instruments (Slide-staining Systems, Scanners, Tissue-processing Systems, Other Instruments).
  • In this report, the tissue diagnostics market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW).

Oncology Molecular Diagnostics Global Market Research Report 2022: PCR, ISH, INNAT, Chips & Microarrays, Sequencing, Mass Spectroscopy, & TMA Analysis & Forecasts 2016-2021, 2021-2026F, 2031F - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 30, 2022
Genetics, Health, Oncology, Danaher Corporation, ICON plc, ISH, BD (company), EGFR, Breast cancer, Leica Biosystems, Cancer, Female, Immunohistochemistry, Polymerase chain reaction, Large-cell lung carcinoma, Hologic, Protein, Gen-Probe, Incidence, Cepheid variable, Blood, Beckman Coulter, Siemens Healthineers, Lung, American Cancer Society, Organization, Hospital, IHC, PCR, Saliva, FDA, Roche Diagnostics, Prostate, Mutation, ICON, Genomics, Acquisition, Growth, Health, TMA, Stanford University v. Roche Molecular Systems, Inc., Patient, Medical imaging, Cobas

Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen-Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.

Key Points: 
  • Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen-Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.
  • The high cost of molecular diagnostic tests is a key factor hampering the growth of the oncology molecular diagnostics market.
  • Therefore, the high cost of molecular diagnostic tests is expected to hamper the growth of the oncology molecular diagnostics market.
  • The countries covered in the oncology molecular diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

PROOF DIAGNOSTICS EXPANDS LEADERSHIP TEAM WITH STRATEGIC GROWTH HIRE

Retrieved on: 
Thursday, June 23, 2022
Solution, Senior, Siemens Healthineers, COVID-19, Diagnosis, Head, CEO, Molecular diagnostics, Strategic management, Business, CRISPR, Hologic, Corporate development, Growth, Roche, Health, Gen-Probe, Multimedia, Management

He will spearhead the company's overarching growth and business development strategy, reporting directly to CEO and co-founder, Sid Shenai.

Key Points: 
  • He will spearhead the company's overarching growth and business development strategy, reporting directly to CEO and co-founder, Sid Shenai.
  • Prior to joining Proof Diagnostics, Mr. Henry served as Head of Corporate Strategy and Business Development at Roche-subsidiary GenMark Dx.
  • Before Roche, he served on the Corporate Strategy team at Siemens Healthineers, where he focused on internal management consulting for the company's Diagnostics division, working across the Lab Diagnostics, Molecular Diagnostics, and Point-of-Care business segments.
  • Proof Diagnostics, Inc. has established itself as an innovative healthcare technology company focused on delivering innovative solutions in molecular diagnostics.